Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

The International Journal of Breast Cancer is a premier academic platform dedicated to advancing the field of breast cancer research and treatment. Published by HINDAWI LTD, this journal embraces an Open Access model since 2011, ensuring that cutting-edge research is readily accessible to all, facilitating the dissemination of knowledge across the global scientific community. With its ISSN 2090-3170 and E-ISSN 2090-3189, the journal caters to a diverse audience comprising researchers, clinicians, and students engaged in oncology and pharmacology. The journal has consistently demonstrated its relevance, classified in the Q4 quartile for Cancer Research and the Q3 quartile for both Oncology and Pharmacology in the latest rankings. It currently ranks #151/272 in the Medicine & Pharmacology category and #232/404 in Medicine & Oncology according to Scopus, showcasing its adaptive role in an evolving field. Commencing in 2013 and continuing through to 2024, the journal is positioned to be an essential resource, addressing critical topics and fostering innovative solutions for breast cancer challenges.

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

Imagerie de la Femme, published by ELSEVIER MASSON, is a pivotal journal in the field of women’s health and surgical practices, holding an ISSN of 1776-9817 and an E-ISSN of 2214-8485. Established in 2005 and converging through to 2024, this journal is dedicated to disseminating high-quality research and innovative findings that contribute to the understanding and advancement of surgical techniques and imaging modalities specifically tailored to women. Despite its current Q3 ranking in Surgery and Scopus rank of 536/551, the journal is increasingly recognized for its focus on emerging trends and critical issues within the discipline. As a scholarly platform, it offers an essential resource for researchers, healthcare professionals, and students alike, promoting knowledge exchange and fostering advancements in the nuanced realm of female surgical health. With its commitment to enhancing clinical practice and patient outcomes, Imagerie de la Femme plays an important role in shaping future research and educational efforts in this vital area of medicine.

ACTA ONCOLOGICA is a prestigious multidisciplinary journal published by Medical Journal Sweden AB, dedicated to advancing cancer research and clinical practice. As a key resource in the field of oncology, the journal aims to publish high-quality articles that cover significant developments in cancer biology, treatment modalities, and innovative imaging techniques. With an ISSN of 0284-186X and an E-ISSN of 1651-226X, ACTA ONCOLOGICA operates in the United Kingdom and is recognized for its substantial impact, currently holding a Q2 ranking in the categories of Hematology, Medicine (miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging in 2023. The journal’s commitment to disseminating pivotal research is reflected in its inclusion in Scopus, with rankings placing it in the top half of its fields. Though it does not currently offer Open Access, it remains an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest trends and findings in oncology. Established in 1963, the journal continues to be a cornerstone of cancer research well into 2024.

Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.